BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.630
+0.020 (1.24%)
At close: Nov 14, 2025, 4:00 PM EST
1.611
-0.019 (-1.14%)
After-hours: Nov 14, 2025, 7:57 PM EST

BioXcel Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
3619866025691,126
Upgrade
Market Cap Growth
22.54%-78.51%-85.65%5.82%-49.47%327.27%
Upgrade
Enterprise Value
1098396462317895
Upgrade
Last Close Price
1.635.9847.20343.68325.28739.20
Upgrade
PS Ratio
16.278.1962.581605.17--
Upgrade
PB Ratio
--0.20-1.537.842.575.45
Upgrade
P/TBV Ratio
---7.842.575.45
Upgrade
EV/Sales Ratio
144.6236.6969.821233.33--
Upgrade
Debt / Equity Ratio
-1.23-1.11-1.791.220.010.01
Upgrade
Asset Turnover
0.020.040.010.00--
Upgrade
Inventory Turnover
0.971.610.63---
Upgrade
Quick Ratio
0.961.352.405.9013.9818.00
Upgrade
Current Ratio
1.181.682.656.1714.2118.33
Upgrade
Return on Equity (ROE)
---1766.94%-111.08%-49.93%-70.35%
Upgrade
Return on Assets (ROA)
-67.31%-72.30%-74.95%-44.81%-29.10%-40.13%
Upgrade
Return on Capital (ROIC)
-158.82%-148.97%-97.39%-50.73%-31.02%-43.59%
Upgrade
Return on Capital Employed (ROCE)
-721.90%-402.40%-361.00%-92.30%-48.00%-39.50%
Upgrade
Earnings Yield
-191.35%-321.18%-207.35%-27.54%-18.80%-7.30%
Upgrade
FCF Yield
-163.31%-388.15%-179.52%-22.51%-14.52%-5.92%
Upgrade
Buyback Yield / Dilution
-235.79%-39.21%-4.00%-6.23%-21.63%-33.11%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q